ReviewDrugs1999
A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy.
Review in Drugs, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 64 citations in OpenAlex.
- Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy.BMC gastroenterology · 2013Trial
- Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile.World journal of gastroenterology · 2007Trial
- Breath and string test: a diagnostic package for the identification of treatment failure and antibiotic resistance of Helicobacter pylori without the necessity of upper gastrointestinal endoscopy.World journal of gastroenterology · 2005Trial
- Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.World journal of gastroenterology · 2004Trial
- Long-term follow-up ofEmerging microbes & infections · 2020Observational
- Article
- Effects of Clarithromycin-Containing Quadruple Therapy on Helicobacter Pylori Eradication after Nitroimidazole-Containing Quadruple Therapy Failure.Middle East journal of digestive diseases · 2016Article
- Helicobacter pylori persistence in children: distinguishing inadequate treatment, resistant organisms, and reinfection.Current gastroenterology reports · 2012Review
- Rescue Therapy for Helicobacter pylori Infection 2012.Gastroenterology research and practice · 2012Article
- Age-dependent eradication of Helicobacter pylori in Japanese patients.World journal of gastroenterology · 2010Article
- Second-line rescue therapy of helicobacter pylori infection.Therapeutic advances in gastroenterology · 2009Article
- "Rescue" regimens after Helicobacter pylori treatment failure.World journal of gastroenterology · 2008Review
- Helicobacter pylori recurrence and infection rate in Israeli adults.Digestive diseases and sciences · 2008Article
- H pylori recurrence after successful eradication.World journal of gastroenterology · 2008Review
- Effect of smoking on failure of H. pylori therapy and gastric histology in a high gastric cancer risk area of Colombia.Acta gastroenterologica Latinoamericana · 2007Article
- Macrolide resistance conferred by base substitutions in 23S rRNA.Antimicrobial agents and chemotherapy · 2001Review
- Pharmacokinetic considerations in the eradication of Helicobacter pylori.Clinical pharmacokinetics · 2000Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The vast majority of recurrences of Helicobacter pylori infection after apparent eradication are observed during the first year. Almost all of these early recurrences are due to recrudescence rather than reinfection by a new strain. After the first year, the recurrence rates approximate to the rate of natural acquisition of H. pylori infection. By contrast, in developing countries, higher rates of recurrence suggest a major role of real reinfection. Important predictive factors of H. pylori treatment success are compliance and bacterial susceptibility to antibiotics. The new 1-week triple therapies, based on a proton pump inhibitor (PPI) and 2 antibiotics, lead to treatment discontinuation but rarely. If containing a nitroimidazole, their efficacy is reduced to 60 to 80% by pretreatment in vitro resistance. The prevalence of nitroimidazole resistance varies dependent on the geographical area, with rates over 50% in tropical regions. Resistance against macrolides hinders treatment success in 50 to 80% of patients. In the US, south-western Europe and Japan the prevalence of macrolide resistance amounts to about 10%, in other countries about 3%. After failed treatment, acquired resistance is frequent. Testing for resistance is recommended to facilitate the decision for an alternative triple therapy or for quadruple therapy comprising bismuth, metronidazole, tetracycline and a PPI. It seems reasonable to increase the dose of PPI in a retreatment regimen containing amoxicillin. Post-treatment double resistance against nitroimidazoles and macrolides reduces the success of most of the currently evaluated retreatment regimens. To overcome double resistance, high dose PPI plus amoxicillin is one approach, beside other experimental multidrug treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.